Recognizing Tysabri-Related PML: Key Clinical Signals for Patients and Providers

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Education to Legal Accountability

If you or a loved one is taking Tysabri, understanding the subtle early signs of progressive multifocal leukoencephalopathy (PML) can be critical. Building on decades of pharmacovigilance research, this page outlines the clinical signals that may warrant closer monitoring and when to seek medical evaluation.

Tysabri and PML: Medical Evidence and Risk Factors

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for moderate-to-severe active Crohn's disease in adults. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The United States Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, the agency's most stringent safety alert, due to this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically leads to death or severe disability, and healthcare professionals are instructed to monitor patients for any new signs or symptoms suggestive of the condition and to withhold Tysabri immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three primary risk factors for developing PML while on Tysabri have been identified: the presence of anti-JC virus antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressant medications (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive face a higher risk, and these factors should be weighed against expected benefits when initiating or continuing therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is only available through a restricted distribution program called the TOUCH Prescribing Program, which requires patients to read a Medication Guide, understand the risks, and sign an enrollment form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Presentation and Diagnosis of PML

The clinical presentation of PML can include progressive neurological deficits such as weakness, vision changes, cognitive decline, and coordination difficulties. Diagnosis typically involves brain imaging and detection of JC virus DNA in cerebrospinal fluid. The timeline between Tysabri exposure and documented harm can vary, with PML occurring after a few months to several years of treatment, as noted in postmarketing reports of herpes-related infections (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This variability underscores the importance of continuous monitoring. From a medical-risk perspective, the adequacy of warnings regarding Tysabri and PML is a central concern. The FDA boxed warning explicitly states that Tysabri increases PML risk and that the infection usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, questions may arise about whether patients and healthcare providers fully appreciate the magnitude of this risk, particularly in the context of long-term therapy. The TOUCH program aims to mitigate risk through education and restricted distribution, but it does not eliminate the possibility of PML.

Virginia Statute of Limitations for Tysabri-Related Claims

For affected patients in Virginia, attorney-related considerations involve the statute of limitations for filing a claim related to Tysabri-associated PML. In Virginia, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or reasonably should have been discovered. Given that PML can develop insidiously and may not be immediately recognized, the timeline between exposure and documented harm is critical. Patients who develop PML after Tysabri treatment may need to act promptly to preserve their legal rights. Legal counsel can help determine the applicable deadlines based on individual circumstances, including the date of diagnosis and the date when the link to Tysabri was established. The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist, which inhibits lymphocyte migration into the central nervous system. This immunosuppressive effect can reactivate latent JC virus, leading to PML in susceptible individuals. The presence of anti-JCV antibodies indicates prior exposure to the virus, and longer treatment duration increases cumulative immunosuppression, raising PML risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Prior use of other immunosuppressants compounds this risk, as noted in the prescribing information (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Virginia?

In Virginia, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or reasonably should have been discovered. For Tysabri-associated PML, this means the clock typically starts when the patient is diagnosed with PML or when the link to Tysabri is established. Because PML can develop insidiously, it is crucial to consult an attorney promptly to preserve legal rights.

What are the main risk factors for developing PML while on Tysabri?

Three primary risk factors have been identified: the presence of anti-JC virus antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressant medications. Patients who are anti-JCV antibody positive face a higher risk. These factors should be weighed against expected benefits when initiating or continuing therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA Boxed Warning for Tysabri (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.